Natural Killer (NK) cell therapy - Pipeline Insight, 2022
![](/report_cover/8047/natural-killer-nk-cell-therapy-pipeline-insight-2022_en.gif)
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Natural Killer (NK) cell therapy – Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in Natural Killer (NK) cell therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Natural Killer (NK) cell therapy: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis. NK cells are derived from the common lymphoid progenitor cells (lymphoblasts), which also generate B and T lymphocytes. They differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter into the bloodstream. NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. The upcoming technologies and recent advances in understanding the manipulation of NK cell activation and development have led to the hope that NK cells could be harnessed as immunotherapy for cancers and other diseases.
'Natural Killer (NK) cell therapy - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Natural Killer (NK) cell therapy pipeline landscape is provided which includes the disease overview and Natural Killer (NK) cell therapy treatment guidelines. The assessment part of the report embraces, in depth Natural Killer (NK) cell therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Natural Killer (NK) cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Natural Killer (NK) cell therapy Emerging Drugs
Further product details are provided in the report……..
Natural Killer (NK) cell therapy: Therapeutic Assessment
This segment of the report provides insights about the different Natural Killer (NK) cell therapy drugs segregated based on following parameters that define the scope of the report, such as:
Natural Killer (NK) cell therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Natural Killer (NK) cell therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Natural Killer (NK) cell therapy drugs.
Natural Killer (NK) cell therapy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Natural Killer (NK) cell therapy – Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in Natural Killer (NK) cell therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Natural Killer (NK) cell therapy: Overview
Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cells have cytotoxic small granules, which contain special proteins such as perforins and proteases, are known as granzymes in their cytoplasm. Perforins form pores in the cell membrane of the target cell through which the granzymes and associated molecules induce apoptosis. NK cells are derived from the common lymphoid progenitor cells (lymphoblasts), which also generate B and T lymphocytes. They differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus, where they then enter into the bloodstream. NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. The upcoming technologies and recent advances in understanding the manipulation of NK cell activation and development have led to the hope that NK cells could be harnessed as immunotherapy for cancers and other diseases.
'Natural Killer (NK) cell therapy - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Natural Killer (NK) cell therapy pipeline landscape is provided which includes the disease overview and Natural Killer (NK) cell therapy treatment guidelines. The assessment part of the report embraces, in depth Natural Killer (NK) cell therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Natural Killer (NK) cell therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Natural Killer (NK) cell therapy R&D. The therapies under development are focused on novel approaches to treat/improve Natural Killer (NK) cell therapy.
This segment of the Natural Killer (NK) cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Natural Killer (NK) cell therapy Emerging Drugs
- NKTR-214: Nektar therapeutics
- Monalizumab: Innate Pharma
- Bemarituzumab: Five Prime Therapeutics
- ALT 803: ImmunityBio
- CellProtect: XNK Therapeutics
- K-NK002: Kiadis Pharma
- NK-92: ImmunityBio
- WU-NK-101: Wugen
- Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
- ALECSAT: CytoVac
Further product details are provided in the report……..
Natural Killer (NK) cell therapy: Therapeutic Assessment
This segment of the report provides insights about the different Natural Killer (NK) cell therapy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Natural Killer (NK) cell therapy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Natural Killer (NK) cell therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Natural Killer (NK) cell therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Natural Killer (NK) cell therapy drugs.
Natural Killer (NK) cell therapy Report Insights
- Natural Killer (NK) cell therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Natural Killer (NK) cell therapy drugs?
- How many Natural Killer (NK) cell therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Natural Killer (NK) cell therapy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Natural Killer (NK) cell therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Natural Killer (NK) cell therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Natural Killer (NK) cell therapy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
NKTR-214: Nektar therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CellProtect: XNK Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Natural Killer (NK) cell therapy Key Companies
Natural Killer (NK) cell therapy Key Products
Natural Killer (NK) cell therapy- Unmet Needs
Natural Killer (NK) cell therapy- Market Drivers and Barriers
Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
Natural Killer (NK) cell therapy Analyst Views
Natural Killer (NK) cell therapy Key Companies
Appendix
Executive Summary
Natural Killer (NK) cell therapy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
NKTR-214: Nektar therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
CellProtect: XNK Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
Anti-CD33 CAR-NK cells: PersonGen BioTherapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Natural Killer (NK) cell therapy Key Companies
Natural Killer (NK) cell therapy Key Products
Natural Killer (NK) cell therapy- Unmet Needs
Natural Killer (NK) cell therapy- Market Drivers and Barriers
Natural Killer (NK) cell therapy- Future Perspectives and Conclusion
Natural Killer (NK) cell therapy Analyst Views
Natural Killer (NK) cell therapy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Natural Killer (NK) cell therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Natural Killer (NK) cell therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Natural Killer (NK) cell therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Natural Killer (NK) cell therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products